Epalrestat, an aldo-keto reductase family 1 member B1 (AKR1B1) inhibitor [110], is in a Phase II study against triple-negative breast cancer (TNBC) (Figure 5A). Here, AKR1B1 is linked to triple-negative breast carcinoma.